

IMMUCELL CORP /DE/
Form 10-Q
November 09, 2005
[Table of Contents](#)

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2005

OR

“ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

0-15507

Commission file number

IMMUCELL CORPORATION

(Exact name of Registrant as specified in its charter)

Edgar Filing: IMMUCELL CORP /DE/ - Form 10-Q

DELAWARE
(State or other jurisdiction

01-0382980
(I.R.S. Employer

of incorporation)

56 Evergreen Drive

Identification No.)

Portland, ME 04103

(Address of principal executive office and zip code)

(207) 878-2770

(Registrant's telephone number, including area code)

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by a check mark whether the Registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate by a check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Class of Securities:

Outstanding at November 7, 2005:

Common Stock, par value \$0.10 per share

2,847,813

Table of Contents

IMMUCELL CORPORATION

INDEX TO FORM 10-Q

September 30, 2005

| | <u>Page</u> |
|---|--------------------|
| <u>PART I: FINANCIAL INFORMATION</u> | |
| <u>ITEM 1. FINANCIAL STATEMENTS</u> | |
| <u>Balance Sheets at December 31, 2004 and September 30, 2005</u> | 2 |
| <u>Statements of Operations for the three and nine month periods ended September 30, 2004 and 2005</u> | 3 |
| <u>Statements of Cash Flows for the nine month periods ended September 30, 2004 and 2005</u> | 4 |
| <u>Notes to Unaudited Financial Statements</u> | 5-8 |
| <u>ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</u> | 8-11 |
| <u>ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</u> | 11 |
| <u>ITEM 4. CONTROLS AND PROCEDURES</u> | 11 |
| <u>PART II: OTHER INFORMATION</u> | |
| <u>ITEMS 1 THROUGH 6</u> | 12 |
| <u>SIGNATURE</u> | 12 |

Table of Contents**IMMUCELL CORPORATION****PART 1. FINANCIAL INFORMATION****ITEM 1. FINANCIAL STATEMENTS****BALANCE SHEETS**

| | (Unaudited) | |
|---|--------------------------|---------------------------|
| | December 31, 2004 | September 30, 2005 |
| | <u></u> | <u></u> |
| ASSETS | | |
| CURRENT ASSETS: | | |
| Cash and cash equivalents | \$ 1,700,567 | \$ 1,303,079 |
| Short-term investments | 2,749,596 | 3,585,658 |
| Accounts receivable, net of allowance for doubtful accounts of \$13,000 and \$12,000 at December 31, 2004 and September 30, 2005, respectively | 434,591 | 474,356 |
| Inventories | 667,666 | 748,103 |
| Current portion of deferred tax asset | 215,066 | 215,066 |
| Prepaid expenses | 44,913 | 156,555 |
| | <u></u> | <u></u> |
| Total current assets | 5,812,399 | 6,482,817 |
| PROPERTY, PLANT AND EQUIPMENT, at cost: | | |
| Laboratory and manufacturing equipment | 1,701,583 | 1,785,432 |
| Building and improvements | 1,500,559 | 1,554,700 |
| Office furniture and equipment | 123,289 | 131,041 |
| Construction in progress | 7,356 | |
| Land | 50,000 | 50,000 |
| | <u></u> | <u></u> |
| | 3,382,787 | 3,521,173 |
| Less accumulated depreciation | 1,481,643 | 1,679,416 |
| | <u></u> | <u></u> |
| Net property, plant and equipment | 1,901,144 | 1,841,757 |
| DEFERRED TAX ASSET | 674,240 | 544,240 |
| PRODUCT RIGHTS AND OTHER ASSETS , net of accumulated amortization of \$196,000 and \$464,000 at December 31, 2004 and September 30, 2005, respectively | 1,141,886 | 879,572 |
| | <u></u> | <u></u> |
| TOTAL ASSETS | \$ 9,529,669 | \$ 9,748,386 |
| | <u></u> | <u></u> |
| LIABILITIES AND SHAREHOLDERS' EQUITY | | |
| CURRENT LIABILITIES: | | |
| Accrued expenses | \$ 228,609 | \$ 204,877 |
| Accounts payable | 70,143 | 97,396 |
| Income taxes payable | 22,589 | 591 |

Edgar Filing: IMMUCELL CORP /DE/ - Form 10-Q

| | | |
|--|---------------------|---------------------|
| Deferred revenue | 493,151 | 536,531 |
| Total current liabilities | 814,492 | 839,395 |
| Long-term portion of deferred revenue | 986,301 | 616,438 |
| SHAREHOLDERS' EQUITY: | | |
| Common stock, Par value-\$0.10 per share | | |
| Authorized-8,000,000 shares, Issued 3,190,148 and 3,261,148 shares at December 31, 2004 and | | |
| September 30, 2005, respectively | 319,015 | 326,115 |
| Capital in excess of par value | 9,160,991 | 9,344,911 |
| Accumulated deficit | (1,152,128) | (703,975) |
| Treasury stock, at cost 395,498 and 414,002 shares at December 31, 2004 and September 30, 2005, respectively | (599,002) | (674,498) |
| Total shareholders' equity | 7,728,876 | 8,292,553 |
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | \$ 9,529,669 | \$ 9,748,386 |

The accompanying notes are an integral part of these financial statements.

Table of Contents

IMMUCELL CORPORATION

**STATEMENTS OF OPERATIONS FOR THE THREE AND
NINE MONTH PERIODS ENDED SEPTEMBER 30, 2004 AND 2005**

(Unaudited)

| | Three Months Ended | | Nine Months Ended | |
|--|--------------------|------------|-------------------|--------------|
| | September 30, | | September 30, | |
| | 2004 | 2005 | 2004 | 2005 |
| REVENUES: | | | | |
| Product sales | \$ 808,021 | \$ 783,121 | \$ 2,667,691 | \$ 3,059,544 |
| Sale of technology rights | | 239,908 | | 486,483 |
| Grant income | 20,000 | | 30,000 | 37,632 |
| Royalty income | 17,542 | 11,928 | 54,890 | 31,316 |
| Total revenues | 845,563 | 1,034,957 | 2,752,581 | 3,614,975 |
| COSTS AND EXPENSES: | | | | |
| Product costs | 343,047 | 267,268 | 1,102,266 | 1,177,851 |
| Research and development expenses | 272,133 | 357,673 | 735,366 | 924,720 |
| General and administrative expenses | 141,877 | 173,230 | 451,583 | 535,781 |
| Product selling expenses | 108,720 | 93,136 | 314,101 | 316,372 |
| Total costs and expenses | 865,777 | 891,307 | 2,603,316 | 2,954,724 |
| Net operating (loss) income | (20,214) | 143,650 | 149,265 | 660,251 |
| INTEREST AND OTHER INCOME: | | | | |
| Interest income | 15,216 | 36,403 | 40,544 | 87,952 |
| Other income, net | 95 | 5,091 | 354 | 6,243 |
| Net interest and other income | 15,311 | 41,494 | 40,898 | 94,195 |
| (LOSS) INCOME BEFORE INCOME TAXES | (4,903) | 185,144 | 190,163 | 754,446 |
| INCOME TAX EXPENSE | 171 | 75,707 | 81,101 | 306,293 |
| NET (LOSS) INCOME | \$ (5,074) | \$ 109,437 | \$ 109,062 | \$ 448,153 |
| NET (LOSS) INCOME PER COMMON SHARE: | | | | |
| Basic | \$ (0.00) | \$ 0.04 | \$ 0.04 | \$ 0.16 |
| Diluted | \$ (0.00) | \$ 0.04 | \$ 0.04 | \$ 0.15 |
| WEIGHTED AVERAGE COMMON SHARES OUTSTANDING: | | | | |
| Basic | 2,757,817 | 2,847,146 | 2,753,047 | 2,815,295 |

| | | | | |
|---------|-----------|-----------|-----------|-----------|
| Diluted | 2,757,817 | 3,024,188 | 2,956,712 | 2,992,793 |
|---------|-----------|-----------|-----------|-----------|

The accompanying notes are an integral part of these financial statements.

Table of Contents

IMMUCELL CORPORATION

STATEMENTS OF CASH FLOWS FOR THE NINE MONTH PERIODS

ENDED SEPTEMBER 30, 2004 AND 2005

(Unaudited)

| | Nine Months Ended | |
|---|---------------------|---------------------|
| | September 30, | |
| | 2004 | 2005 |
| CASH FLOWS FROM OPERATING ACTIVITIES: | | |
| Net income | \$ 109,062 | \$ 448,153 |
| Adjustments to reconcile net income to net cash provided by operating activities: | | |
| Depreciation | 156,246 | 225,964 |
| Amortization | 30,394 | 268,339 |
| Deferred income taxes | 75,865 | 130,000 |
| Loss on disposal of fixed assets | 1,897 | 3,134 |
| Changes in: | | |
| Accounts receivable | (46,773) | (39,765) |
| Income taxes receivable/payable | | (15,416) |
| Inventories | 75,768 | (80,437) |
| Prepaid expenses and other assets | (31,853) | (117,667) |
| Accrued expenses | (197,011) | (23,732) |
| Accounts payable | 42,458 | 27,253 |
| Deferred revenue | | (326,483) |
| Net cash provided by operating activities | 216,053 | 499,343 |
| CASH FLOWS FROM INVESTING ACTIVITIES: | | |
| Purchase of property, plant and equipment | (257,565) | (169,711) |
| Proceeds from disposal of fixed assets | 4,000 | |
| Maturities of short-term investments | 1,285,061 | 2,749,596 |
| Purchases of short-term investments | (3,245,180) | (3,585,658) |
| Net cash used for investing activities | (2,213,684) | (1,005,773) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | | |
| Proceeds from exercise of stock options | 33,546 | 108,942 |
| Net cash provided by financing activities | 33,546 | 108,942 |
| NET DECREASE IN CASH AND CASH EQUIVALENTS | (1,964,085) | (397,488) |
| BEGINNING CASH AND CASH EQUIVALENTS | 3,356,742 | 1,700,567 |
| ENDING CASH AND CASH EQUIVALENTS | \$ 1,392,657 | \$ 1,303,079 |
| CASH PAID FOR INCOME TAXES | \$ 11,811 | \$ 186,501 |

NON-CASH FINANCING ACTIVITIES:

| | | |
|--|----|-------------------|
| Tax benefits related to stock options | \$ | 6,582 |
| Treasury stock acquired upon exercise of stock options | \$ | 75,496 |
| | | <u> </u> |

The accompanying notes are an integral part of these financial statements.

Table of Contents**IMMUCELL CORPORATION****Notes to Unaudited Financial Statements****September 30, 2005****1. BASIS OF PRESENTATION**

We have prepared the accompanying financial statements without audit and have reflected the adjustments, all of which are of a normal recurring nature, that are, in our opinion, necessary for a fair presentation of the results for the interim periods presented. Certain information and footnote disclosures normally included in the annual financial statements which are prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. Accordingly, we believe that although the disclosures are adequate to make the information presented not misleading, these financial statements should be read in conjunction with the financial statements and the notes to the financial statements as of December 31, 2004, contained in the Company's Annual Report on Form 10-K as filed with the Securities and Exchange Commission.

2. CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS

We consider all highly liquid investment instruments that mature within three months of their purchase dates to be cash equivalents. Short-term investments are classified as held to maturity and are comprised principally of certificates of deposits that mature in more than three months from their purchase and not more than twelve months from the balance sheet date and are held at different financial institutions that are insured by the Federal Deposit Insurance Corporation (FDIC) within FDIC limits of \$100,000 each.

Cash, cash equivalents and short-term investments consist of the following:

| | December 31, 2004 | September 30, 2005 | (Decrease) Increase |
|---------------------------|--------------------------|---------------------------|----------------------------|
| Cash and cash equivalents | \$ 1,700,567 | \$ 1,303,079 | \$ (397,488) |
| Short-term investments | 2,749,596 | 3,585,658 | 836,062 |
| | \$ 4,450,163 | \$ 4,888,737 | \$ 438,574 |

3. INVENTORIES

Inventories consist of the following:

| | December 31, 2004 | September 30, 2005 |
|-----------------|-------------------|--------------------|
| Raw materials | \$ 167,241 | \$ 201,958 |
| Work-in-process | 429,481 | 496,846 |
| Finished goods | 70,944 | 49,299 |
| | <u>\$ 667,666</u> | <u>\$ 748,103</u> |

4. LICENSING AND SALE OF TECHNOLOGY

In November 2004, we capitalized a payment of approximately \$965,000 made to Nutrition 21, Inc. to buy out certain future milestone and royalty payment obligations, which principally resulted in a fully paid, perpetual license related to **Mast Out**[®]. We expect to amortize this intangible asset over the period from December 15, 2004 to December 31, 2007. In December 2004, we received a \$1,500,000 up front payment from Pfizer in connection with a product development and marketing agreement covering **Mast Out**[®]. We expect to recognize this deferred revenue over the period from December 15, 2004 to December 31, 2007. Both of these periods reflect management's estimate of the likely period of product development before royalties could be received on sales of **Mast Out**[®]. If the estimate of December 31, 2007 changes, the period during which the then remaining expense and revenue are recognized would be adjusted accordingly. During the three month period ended September 30, 2005, research and development expenses included approximately \$79,000 of such amortization expense, and total revenues included approximately \$123,000 of such revenue. During the nine month period ended September 30, 2005, research and development expenses included approximately \$238,000 of such amortization expense, and total revenues included approximately \$370,000 of such revenue. We earned an additional \$117,000 during the three month period ended September 30, 2005 under a supplemental agreement covering the supply of additional clinical material to Pfizer. The Pfizer agreement, among other things, also provides for contingent milestone payments as development objectives are achieved and royalties based on any future sales, subject to certain minimums. We expect that revenue from any future milestone payments that we receive from Pfizer before regulatory approval is obtained will be recognized from the date that the milestone is achieved through December 31, 2007. Any such milestone payments received for obtaining regulatory approvals, or after a regulatory approval is obtained, are expected to be recognized when such milestones have been achieved. Any future royalty payments will be recognized as earned based on any future product sales.

Table of Contents**IMMUCELL CORPORATION****Notes to Unaudited Financial Statements (continued)****September 30, 2005****5. INCOME TAXES**

We account for income taxes in accordance with Statement of Financial Accounting Standards (SFAS) No. 109, *Accounting for Income Taxes*. This statement requires that we recognize a current tax liability or asset for current taxes payable or receivable and a deferred tax liability or asset for the estimated future tax effects of temporary differences and carryforwards to the extent they are realizable. The income tax expense aggregated \$171 for the three month period ended September 30, 2004 and \$76,000 (41% of income before income taxes) for the three month period ended September 30, 2005. The income tax expense aggregated \$81,000 (43% of income before income taxes) and \$306,000 (41% of income before income taxes) for the nine month periods ended September 30, 2004 and 2005, respectively. In order to accelerate the utilization of available net operating loss carryforwards in advance of their expiration dates, we elected to increase income for federal income tax purposes by capitalizing research and experimentation expenditures aggregating \$1,731,000 for our 2000 and 2001 tax returns. As a result, we expect to amortize approximately \$173,000 of these capitalized expenditures for each of the five years ending December 31, 2005 to December 31, 2009 as well as \$84,000 for the year ended December 31, 2010 for tax return purposes only. The \$1,500,000 payment from Pfizer received in December 2004 was treated as taxable income, for tax return purposes only. The \$965,000 payment made to Nutrition 21 in November 2004 was treated as an intangible asset and is being amortized over 15 years, for tax return purposes only. We have no remaining net operating loss carryforwards as of December 31, 2004 to offset future taxable income. We believe it is more likely than not that the deferred tax assets will be realized through future tax effects of temporary differences between book income and taxable income. Accordingly, we have not established a valuation allowance for the deferred tax assets, except for the general business credit carryforward of \$62,000 as of December 31, 2004 and September 30, 2005.

6. NET INCOME (LOSS) PER COMMON SHARE

The basic net income (loss) per common share has been computed in accordance with SFAS No. 128, *Earnings Per Share*, by dividing the net income (loss) by the weighted average number of common shares outstanding during the period. Outstanding stock options have not been included in the calculation of the diluted net loss per common share for the three month period ended September 30, 2004 as the effect would be antidilutive, thereby decreasing the diluted net loss per common share. The diluted net income per common share for the three month period ended September 30, 2005 and the nine month periods ended September 30, 2004 and 2005 reflects the potential dilution from outstanding stock options as shown in the table below.

| | Three Months Ended | | Nine Months Ended | |
|---|---------------------------|-------------|--------------------------|-------------|
| | September 30, | | September 30, | |
| | 2004 | 2005 | 2004 | 2005 |
| Weighted average number of shares outstanding during the period | 2,757,817 | 2,847,146 | 2,753,047 | 2,815,295 |
| Dilutive stock options | | 441,639 | 560,972 | 441,639 |
| Shares that could have been repurchased with the proceeds from the dilutive stock options | | (264,597) | (357,307) | (264,141) |

| | | | | |
|---|-----------|-----------|-----------|-----------|
| Diluted number of shares outstanding during the period | 2,757,817 | 3,024,188 | 2,956,712 | 2,992,793 |
| Outstanding stock options not included in the calculation because the effect would be anti-dilutive | 573,139 | | 3,333 | |

7. EMPLOYEE STOCK-BASED COMPENSATION

We measure compensation related to employee stock-based compensation plans in accordance with the intrinsic value method of Accounting Principles Board Opinion No. 25, *Accounting for Stock Issued to Employees*, and we elect to disclose the pro forma impact of accounting for stock-based compensation plans under the provisions of SFAS No. 123, *Accounting for Stock-Based Compensation* and SFAS No. 148, *Accounting for Stock-Based Compensation-Transition and Disclosure*. Accordingly, no stock-based employee compensation cost has been recognized for these plans. In December 2004, the FASB issued Revised Statement of Financial Accounting Standards No. 123, *Share-Based Payments (FAS 123R)*, revising FASB Statements No. 123 and 95. FAS 123R eliminates the ability to account for stock-based compensation transactions using APB Opinion No. 25 and generally requires us to recognize compensation costs for stock-based payments using the fair-value-based method. Implementation of the provisions of FAS 123R has been deferred and shall be effective beginning January 1, 2006. Had compensation cost for our stock plans been determined consistent with the provisions of FAS 123R, our net (loss) income and basic and diluted net (loss) income per share would have been reduced to the pro forma amounts indicated in the table below:

Table of Contents**IMMUCELL CORPORATION****Notes to Unaudited Financial Statements (continued)****September 30, 2005**

| | Three Months Ended | | Nine Months Ended | |
|--|---------------------------|-------------|--------------------------|-------------|
| | September 30, | | September 30, | |
| | 2004 | 2005 | 2004 | 2005 |
| Net (loss) income, as reported | \$ (5,074) | \$ 109,437 | \$ 109,062 | \$ 448,153 |
| Less: Pro forma stock-based employee compensation expense determined under the fair value based method, net of related tax effects | 12,408 | 6,158 | 34,652 | 15,384 |
| Pro forma net (loss) income | \$ (17,482) | \$ 103,279 | \$ 74,410 | \$ 432,769 |
| Net (loss) income per share: | | | | |
| Basic: as reported | \$ (0.00) | \$ 0.04 | \$ 0.04 | \$ 0.16 |
| Basic: pro forma | \$ (0.01) | \$ 0.04 | \$ 0.03 | \$ 0.15 |
| Diluted: as reported | \$ (0.00) | \$ 0.04 | \$ 0.04 | \$ 0.15 |
| Diluted: pro forma | \$ (0.01) | \$ 0.03 | \$ 0.03 | \$ 0.14 |

8. SEGMENT AND SIGNIFICANT CUSTOMER INFORMATION

Pursuant to SFAS No. 131, *Disclosures about Segments of an Enterprise and Related Information*, we operate in one reportable business segment, that being the development, acquisition, manufacture and sales of products that improve the health and productivity of cows for the dairy and beef industries. Almost all of the Company's internally funded research and development expenses are in support of products that improve the health and productivity of cows for the dairy and beef industries. The significant accounting policies of this segment are the same as those described in Note 2 to the Company's Annual Report on Form 10-K for the year ended December 31, 2004.

Our primary customers for the majority (90% and 88% for the three month periods ended September 30, 2004 and 2005, respectively, and 90% and 85% for the nine month periods ended September 30, 2004 and 2005, respectively) of our product sales are in the United States dairy and beef industries. Sales to customers outside of the United States, who are in the dairy and beef industries, aggregated 10% and 12% of product sales for the three month periods ended September 30, 2004 and 2005, respectively, and 10% and 12% for the nine month periods ended September 30, 2004 and 2005, respectively. Sales made to Walco International, Inc. aggregated 14% and 16% of total product sales during the three month periods ended September 30, 2004 and 2005, respectively, and 18% and of total product sales during both the nine month periods

ended September 30, 2004 and 2005. This customer accounted for 16% and 17% of our outstanding accounts receivable as of December 31, 2004 and September 30, 2005, respectively. Sales made to Vet Pharm, Inc. aggregated 13% of total product sales during the three month period ended September 30, 2005. This customer accounted for less than 10% of our sales during the other periods being reported. This customer accounted for 12% of our outstanding accounts receivable as of September 30, 2005 and less than 10% of our outstanding accounts receivable as of December 31, 2004.

9. COMMON STOCK

On April 3, 2003, we announced that our Board of Directors had approved a plan to repurchase up to 100,000 shares of our common stock as market conditions warrant because of our belief that the stock had been trading at undervalued levels at that time and thus represented a good investment. Repurchases under the plan may be made from time to time at the discretion of management. There is no guarantee as to the exact number of shares to be repurchased, and no time limit was set for the completion of the repurchase plan. Our present intention is to hold repurchased shares as treasury stock to be used for general corporate purposes. The maximum of 100,000 shares represented approximately 3.7% of our outstanding common stock as of March 31, 2003. During the three months ended June 30, 2003, we repurchased 5,900 shares of our common stock at a total cost of approximately \$12,267 (an average purchase price of \$2.08 per share) under this plan. As of November 7, 2005, no additional shares had been repurchased. The repurchase of shares under this plan has been limited to date because the share price has generally traded above the level experienced around the time that we adopted the repurchase plan.

During June 2005, two outside directors and two executive officers who are also directors exercised stock options for an aggregate of 71,000 shares of common stock. The exercise of these options was paid for with \$108,942 in cash and the surrender of 18,504 shares of previously-owned common stock having an aggregate market value of \$75,496 at the time of exercise. The 18,504 reacquired shares have been recorded as treasury stock.

Table of Contents

IMMUCELL CORPORATION

Notes to Unaudited Financial Statements (continued)

September 30, 2005

In September 1995, our Board of Directors adopted a Common Stock Rights Plan, the terms of which were set forth in a Rights Agreement with American Stock Transfer & Trust Co., as a Rights Agent. Pursuant to the Rights Agreement, we issued certain Rights to all holders of our Common Stock. Under the Rights Agreement, the Rights expire on the earlier to occur of the Redemption Date (as defined) or the Final Expiration Date (originally defined to be September 19, 2005). On June 8, 2005, our Board voted to authorize an amendment of the Rights Agreement to extend the Final Expiration Date by an additional three years, to September 19, 2008. As of June 30, 2005, we entered into an amendment to the Rights Agreement with the Rights Agent reflecting such extension. No other changes were made to the terms of the Rights or the Rights Agreement.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

RESULTS OF OPERATIONS FOR THE THREE AND NINE MONTH PERIODS ENDED SEPTEMBER 30, 2005

Product sales decreased by 3%, or \$25,000, to \$783,000 during the three month period ended September 30, 2005 in comparison to \$808,000 during the same period in 2004. Despite the small decline in product sales of \$25,000 during the three month period ended September 30, 2005, product sales increased by 12%, or \$181,000, during the six month period ended September 30, 2005 in comparison to the same period in 2004. Product sales increased by 15%, or \$392,000, to \$3,060,000 during the nine month period ended September 30, 2005 in comparison to \$2,668,000 during the same period in 2004. Sales of **First Defense**® are normally seasonal with highest sales expected in the first quarter and lower sales expected during the second and third quarters. Sales of **First Defense** increased by 11% during the nine month period ended September 30, 2005 in comparison to the same period in 2004. Sales have been positively affected by the increase in the price that dairy producers are paid for the milk that they produce and sell. Sales of **Wipe Out**® **Dairy Wipes** increased by 22% during the nine month period ended September 30, 2005 in comparison to the same period in 2004. Domestic sales of this premium product have been challenged by less expensive competitive products and by the continuing economic pressure in the U.S. dairy industry that is forcing many small producers out of business. A decrease in the domestic sales of this product was more than offset by new foreign sales in 2005.

Total revenues increased by 22%, or \$189,000, to \$1,035,000 during the three month period ended September 30, 2005 in comparison to the same period in 2004. Total revenues increased by 31%, or \$862,000, to \$3,615,000 during the nine month period ended September 30, 2005 in comparison to the same period in 2004. We recognized \$240,000 and \$486,000 in revenue from the sale of technology rights during the three and nine month periods ended September 30, 2005, respectively, related to the \$1,500,000 up front payment received from Pfizer in December 2004 and a \$225,000 supplemental clinical material supply agreement. No revenue from the sale of technology rights was earned during the same periods in 2004. We earned no grant income during the three months ended September 30, 2005 as compared to \$20,000 of grant income during the same period in 2004. We earned \$38,000 of grant income during the nine months ended September 30, 2005 as compared to \$30,000 during the same period in 2004. This grant income supported the development of a bovine milk immunoglobulin supplement to prevent diarrhea in humans. We earned royalties of \$12,000 and \$18,000 during the three month periods ended September 30, 2005 and 2004, respectively, and \$31,000 and \$55,000 during the nine month periods ended September 30, 2005 and 2004, respectively. Royalty income has no relation to the sale of the products that we manufacture and is earned on the sale of whey protein isolate by a licensee to certain rights to our milk protein purification technology.

Edgar Filing: IMMUCELL CORP /DE/ - Form 10-Q

Gross margin as a percentage of product sales was 66% and 58% during the three month periods ended September 30, 2005 and 2004, respectively. The total gross margin increased by 11%, or \$51,000, to \$516,000 during the three month period ended September 30, 2005, as compared to the same period in 2004. Gross margin as a percentage of product sales was 62% and 59% during the nine month periods ended September 30, 2005 and 2004, respectively. The total gross margin increased by 20%, or \$316,000, to \$1,882,000 during the nine month period ended September 30, 2005, as compared to the same period in 2004. We earn a higher gross margin on products that we have developed, such as **First Defense**[®], and a lower gross margin on acquired products, such as **Wipe Out**[®] **Dairy Wipes**. We have experienced some efficiencies in the cost to manufacture **First Defense**[®] as sales volume and inventory production increase.

During the three month period ended September 30, 2005, research and development expenses increased by 31%, or \$86,000, to \$358,000, as compared to the same period in 2004. During the nine month period ended September 30, 2005, research and development expenses increased by 26%, or \$189,000, to \$925,000, as compared to the same period in 2004. During the three and nine month periods ended September 30, 2005, this expense included \$79,000 and \$238,000,

Table of Contents

IMMUCELL CORPORATION

respectively, in amortization of the intangible asset pertaining to the November 2004 buy out of certain future milestone and royalty payment obligations under our **Mast Out**[®] license from Nutrition 21. Research and development expenses aggregated 35% and 32% of total revenues during the three month periods ended September 30, 2005 and 2004, respectively. Research and development expenses exceeded grant income and revenue from the sale of technology rights by \$118,000 (which net amount equaled 15% of product sales) during the three month period ended September 30, 2005 and by \$252,000 (which net amount equaled 31% of product sales) during the three month period ended September 30, 2004. Research and development expenses aggregated 26% and 27% of total revenues during the nine month periods ended September 30, 2005 and 2004, respectively. Research and development expenses exceeded grant income and revenue from the sale of technology rights by \$401,000 (which net amount equaled 13% of product sales) during the nine month period ended September 30, 2005 and by \$705,000 (which net amount equaled 26% of product sales) during the nine month period ended September 30, 2004. No revenue from the sale of technology rights was earned during the three or nine month periods ended September 30, 2004.

During 2000, we initiated the development of **Mast Out**[®], a Nisin-based treatment for mastitis in lactating dairy cows. Nisin, a natural antibacterial peptide, is also the active ingredient in our product, **Wipe Out**[®] **Dairy Wipes**. **Mast Out**[®] has become the primary focus of our research and development investment. In December 2004, we entered into a product development and marketing agreement with Pfizer Animal Health, a division of Pfizer, Inc. for **Mast Out**[®]. We granted Pfizer a worldwide, exclusive, long-term license to sell the product. In return, we received an up front payment of \$1,500,000 from Pfizer and are eligible to receive contingent milestone payments and royalties on sales. Pfizer is responsible for clinical, regulatory and commercial manufacturing development. During the first half of 2005, we completed our initial contractual obligation to supply clinical trial material to Pfizer. During the third quarter of 2005, we completed approximately two-thirds of our supplemental contractual obligation to supply additional clinical trial material to Pfizer. We are also continuing to fulfill our contractual obligation to perform stability testing and purity analysis of the clinical trial material. These activities, together with additional Nisin process development for both **Mast Out**[®] and **Wipe Out**[®] **Dairy Wipes**, comprised most of our research and development expenses during the first nine months of 2005.

While we continue our efforts with internally and externally funded product development programs, we also seek to acquire new products and technologies that fit with our sales focus on the dairy and beef industries. There are other applications of our Nisin technology that may lead to potential product applications, including a treatment for mastitis in dry (non-lactating) cows.

Capitalizing on certain scientific knowledge gained while working on a milk antibody product to prevent *Cryptosporidium parvum* infections in humans during the early 1990's, we developed the water diagnostic test, **Crypto-Scan**[®]. This non-animal health product utilizes our immunomagnetic separation technology. Despite gaining U.K. regulatory approval in November 2000, sales of this product have been insignificant. In April 2005, we entered into an exclusive distribution agreement with TCS Biosciences Ltd. of England covering sales of this product in the European Union, Japan, and Australia. TCS has made some modifications to the test kit and obtained the necessary regulatory approval of the modified test. TCS has initiated commercial sales of this product under their name, Isolate Cryptosporidium. We would benefit from the exclusive supply agreement if TCS achieves market acceptance of the product.

During the three month period ended September 30, 2005, general and administrative expenses increased by 22%, or \$31,000, to \$173,000 as compared to \$142,000 during the same period in 2004. During the nine month period ended September 30, 2005, general and administrative expenses increased by 19%, or \$84,000, to \$536,000 as compared to \$452,000 during the same period in 2004. These increases resulted principally from increased personnel and outside consulting expenses. During the three month period ended September 30, 2005, product selling expenses decreased by 14%, or \$16,000, to \$93,000, as compared to the same period in 2004, aggregating 12% and 13% of product sales during the three month periods ended September 30, 2005 and 2004, respectively. During the nine month period ended September 30, 2005, product selling expenses increased by less than 1%, or \$2,000, to \$316,000, as compared to the same period in 2004, aggregating 10% and 12% of product sales during the nine month periods ended September 30, 2005 and 2004, respectively. The ratio of product selling expenses to product sales decreased during the nine month period ended September 30, 2005 in comparison to the same period in 2004 due to the increase in product sales. Our objective is to maintain the ratio of product selling expenses to product sales below 15% on an annual basis.

The income (loss) before income taxes for the three month periods ended September 30, 2005 and 2004 was \$185,000 and \$(5,000), respectively. The net income for the three months ended September 30, 2005 of \$109,000 (\$0.04 per diluted share) contrasts to a net loss of \$(5,000) for the three months ended September 30, 2004. The effective income tax rate was 41% for the three month period ended September 30, 2005. Income before income taxes for the nine month periods ended September 30, 2005 and 2004 was \$754,000 and \$190,000, respectively. The net income for the nine months ended September 30, 2005 of \$448,000 (\$0.15 per diluted share) compares to net income of \$109,000 (\$0.04 per diluted share) for the nine months ended September 30, 2004. The effective income tax rate was 41% and 43% for the nine month periods ended September 30, 2005 and 2004, respectively.

Table of Contents

IMMUCELL CORPORATION

LIQUIDITY AND CAPITAL RESOURCES

Cash, cash equivalents and short-term investments increased by 10%, or \$439,000, to \$4,889,000 at September 30, 2005 from \$4,450,000 at December 31, 2004. Net cash provided by operating activities amounted to \$499,000 during the nine months ended September 30, 2005 as compared to \$216,000 during the nine months ended September 30, 2004, due principally to the increase in net income. Total assets increased by 2%, or \$219,000, to \$9,748,000 at September 30, 2005 from \$9,530,000 at December 31, 2004. The Company has no outstanding bank debt. Net working capital increased by 13%, or \$646,000, to \$5,643,000 at September 30, 2005 from \$4,998,000 at December 31, 2004. Shareholders equity increased by 7%, or \$564,000, to \$8,293,000 at September 30, 2005 from \$7,729,000 at December 31, 2004.

The December 2004 product development and marketing agreement with Pfizer for **Mast Out**® provides for contingent milestone payments as development objectives are achieved and royalties based on any future sales, subject to certain minimums. For instance, we received \$1,500,000 upon signing of the agreement. Subject to the satisfaction of designated conditions, we are eligible to receive an additional \$750,000 in milestone payments during the second or third quarters of 2006. Additional milestone payments may be earned in the future in connection with certain clinical trial objectives, regulatory approvals and patent issuances. During the first half of 2005, we satisfied our contractual obligation to supply clinical trial material to Pfizer, and Pfizer initiated certain clinical trials with this material. In May 2005, we entered into a supplemental agreement with Pfizer, under which we are eligible to earn approximately \$181,000 for supplying additional clinical trial material to Pfizer in the second half of 2005 and approximately \$44,000 to perform stability testing of this material during the 30 month period ending December 31, 2007. We recognized \$117,000 of this revenue during the three month period ended September 30, 2005.

We believe that we have sufficient capital resources to meet our working capital requirements and to finance our ongoing business operations during at least the next twelve months.

FORWARD-LOOKING STATEMENTS

This Quarterly Report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to factors that may affect the dairy industry and future demand for our products, the estimated timing of future development work and commercialization of our products, anticipated applications for future regulatory approvals, anticipated future research efforts, sources of possible future milestone payments and other revenue, the future adequacy of our working capital, future profitability, future expense ratios and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in development, testing, regulatory approval, production and marketing of our products, competition within our anticipated product markets, the uncertainties associated with product development, and other risks detailed from time to time in filings we make with the Securities and Exchange Commission, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Such statements are based on our current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned or referred to in this Quarterly Report.

RISK FACTORS

Edgar Filing: IMMUCELL CORP /DE/ - Form 10-Q

The sale and development of our products are subject to financial, efficacy, regulatory and market risks. We cannot be sure that we will be able to maintain the regulatory compliance required to continue selling our products or that we will be able to finance the development of new product opportunities or that, if financed, the new products will be found to be efficacious and gain the appropriate regulatory approval. Furthermore, if regulatory approval is obtained, there can be no assurance that the market estimates will prove to be accurate or that market acceptance at a profitable price level can be achieved or that the products can be profitably manufactured. We are heavily dependent on the successful development of new products for future growth. One such major effort is our product development and marketing agreement with Pfizer, under which that company will largely control the development and commercialization of **Mast Out**®. Under our agreement, Pfizer has broad discretion over the development efforts and retains the right to terminate the license subject to certain conditions.

We are a small company with approximately 25 employees. As such, we rely on certain key employees to support different operational functions, with little redundancy in capacity. The loss of any of these key employees could adversely affect our operations until a qualified replacement is hired and trained.

Table of Contents

IMMUCELL CORPORATION

We believe that supplies and raw materials for the production of our products are available from more than one source. Our policy is to maintain more than one source of supply for the components used in our products. However, there is a risk that we could have difficulty in efficiently acquiring essential supplies. We are dependent on our manufacturing operations and facility at 56 Evergreen Drive in Portland, Maine for the production of **First Defense**® and **Wipe Out**® **Dairy Wipes** and for the production of clinical trial material for Pfizer. The specific antibodies that we purify for **First Defense**® and the Nisin we produce by fermentation for **Wipe Out**® **Dairy Wipes** and for Pfizer are not readily available from other sources. Any disruption in the services at this facility could adversely affect the production of inventory.

The dairy industry in the United States has been facing very difficult economic pressures. After declining in 2002 to price levels common in the 1970 s, the price of milk has increased, but the number of small dairy farmers continues to decrease. The financial insecurity of our primary customer base is a risk to our ability to maintain and grow sales at a profitable level.

First Defense® is sold in the United States subject to a product license approval from the USDA, first obtained in 1991. The potency of serial lots is directly traceable to the original serial used to obtain the product performance claims (the Reference Standard). Due to the unique nature of the **First Defense**® label claims, host animal re-testing is not required as long as periodic laboratory analyses continue to support the stability of stored Reference Standard. To date, these analyses have demonstrated strong stability. However, if, at any time, the USDA does not approve the requalification of the Reference Standard, additional clinical studies could be required to meet regulatory requirements and allow for continued sales of the product.

Wipe Out® **Dairy Wipes** are permitted to be sold without a New Animal Drug Application approval, in accordance with the FDA s Compliance Policy Guide 7125.30 (Teat Dips and Udder Washes for Dairy Cows and Goats). At some time in the future, this category of products may be required to comply with the NADA approval requirements. The enforcement by the FDA of full drug regulations on this product would likely make it not economical to continue manufacturing it.

The potential for epidemics of bovine diseases such as Foot and Mouth Disease, Bovine Tuberculosis, Brucellosis and Bovine Spongiform Encephalopathy (BSE) presents a risk to us and our customers. Documented cases of BSE in the U.S. have led to an overall tightening of regulations pertaining to ingredients of animal (especially bovine) origin. **First Defense**® is considered a veterinary medicine rather than a feed ingredient, and it is manufactured from bovine milk and colostrum, which is not considered a BSE risk material. Future regulatory action to increase protection of the human food supply could affect **First Defense**®, although presently we do not anticipate that this will be the case.

The threat of biological terrorism is a risk to both the economic health of our customers and to our ability to economically acquire and collect good quality raw material from our contract farms. Any act of widespread bioterrorism against the dairy industry could adversely affect our operations.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable

ITEM 4. CONTROLS AND PROCEDURES

Our management, with the participation of the individual who serves as our principal executive and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2005. Based on this evaluation, that officer concluded that our disclosure controls and procedures were effective as of that date. There was no change in our internal control over financial reporting that occurred during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Disclosure controls and procedures are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file under the Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officer, as appropriate to allow timely decisions regarding required disclosures.

Table of Contents

IMMUCELL CORPORATION

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

Not applicable

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Not applicable

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

Not applicable

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

Not applicable

ITEM 5. OTHER INFORMATION

Not applicable

ITEM 6. EXHIBITS

Exhibit 31 Certifications required by Rule 13a-14(a).

Exhibit 32 Certification pursuant to Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

SIGNATURE

Edgar Filing: IMMUCELL CORP /DE/ - Form 10-Q

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ImmuCell Corporation

Registrant

Date: November 9, 2005

By: /s/ Michael F. Brigham

Michael F. Brigham

President, Chief Executive Officer

and Principal Financial Officer